| Ghrelin (human)Endogenous agonist for ghrelin receptor (GHS-R1a) |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
Ghrelin (human) Dilution Calculator
calculate
Ghrelin (human) Molarity Calculator
calculate
| Cas No. | 258279-04-8 | SDF | Download SDF |
| Formula | C149H249N47O42 | M.Wt | 3370.9 |
| Solubility | Soluble in H2O | Storage | Desiccate at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Ghrelin is a specific endogenous ligand for the GHS receptor which can stimulate strong increase in circulating GH levels both in vitro and in vivo in a dose-dependent manner, Human acylated ghrelin is the major active form that can cross the blood-brain barrier, and has an effection on the activity of arcute neurones with a much stronger affinity (IC50, 0.3×10-9M) than GHSR antagonist (D-Lys3)-GHRP-6 (IC50, 0.9×10-6M)[1].
Ghrelin has effects in stimulating appetite, increasing secretion of GH and hypo-catabolism, improvement of gastrointestinal motility, increasing cardiac output, improvement of pulmonary function and anti-inflammatory effect.
Clinical applications of ghrelin in total gastrectomy, esophagectomy and neoadjuvant chemotherapy can stimulate food intake, improve guality of life scores and minimize adverse events. Recently, ghrelin as a effective approach in the management of anorexia nervosa[2],cachexia[3], BW[4] and appetite loss[5], systemic inflammatory response[6]and cancer[7]. In conclusion, ghrelin is a promising candidate for treating catabolic states and enhancing immune function in cachexia or acquired immunodeficiency syndrome, as well as for treating eating disorders such as obesity and anorexia nervosa.
References:1.M. Traebert,* T. Riediger,† S. Whitebread,* E. Scharrer† and H. A. Schmid*. Ghrelin Acts on Leptin-Responsive Neurones in the Rat Arcuate Nucleus. Journal of Neuroendocrinology, 2002, Vol. 14, 580–5862.Hotta M, Ohwada R, Akamizu T, Shibasaki T, Takano K, KangawaK.Ghrelinincreaseshungerandfoodintakeinpatients withrestricting-typeanorexianervosa:apilotstudy.EndocrJ. 2009;56:1119–28.3.Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005;128:1187–93.4.AdachiS,TakiguchiS,OkadaK, YamamotoK, YamasakiM, Miyata H, et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology. 2010;138:1312–20.5.Hiura Y, Takiguchi S, Yamamoto K, Kurokawa Y, Yamasaki M, NakajimaK, et al. Fall inplasmaghrelinconcentrationsafter cisplatin-based chemotherapy in esophageal cancer patients. Int J Clin Oncol. 2012;17:316–23.6.CheyuoC,JacobA,WangP.Ghrelin-mediatedsympathoinhibition and suppression of inflammation in sepsis. Am J Physiol Endocrinol Metab. 2012;302:E265–72.7.Yoshida N, Watanabe M, Baba Y, Iwagami S, Ishimoto T, Iwatsuki M, et al.Risk factors for pulmonary complications after esophagectomy for esophageal cancer. Surg Today. 2014;44:526–32.
